NCT07215078View on ClinicalTrials.gov

Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 8, 2025

Primary Completion Date

April 16, 2026

Study Completion Date

May 7, 2026

Conditions
Healthy Volunteer
Interventions
DRUG

atirmociclib (PF-07220060)

Open-label, two-period, cross-over study to evaluate dose proportionality of atirmociclib (PF-07220060) pharmacokinetics when administered under fed condition to healthy participants

Trial Locations (1)

06511

Pfizer Clinical Research Unit - New Haven, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT07215078 - Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants | Biotech Hunter | Biotech Hunter